MARKET

NVO

NVO

Novo Nordisk
NYSE

Real-time Quotes | Nasdaq Last Sale

74.07
-0.06
-0.08%
Pre Market: 73.75 -0.32 -0.43% 09:07 05/06 EDT
OPEN
74.00
PREV CLOSE
74.13
HIGH
74.11
LOW
73.65
VOLUME
2.04K
TURNOVER
--
52 WEEK HIGH
75.86
52 WEEK LOW
61.53
MARKET CAP
131.51B
P/E (TTM)
25.06
1D
5D
1M
3M
1Y
5Y
Novo Nordisk A/S to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / May 5, 2021 / Novo Nordisk A/S (NYSE:NVO) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 5, 2021 at 1:00 PM Eastern Time.To listen to the event live or access a replay of th...
ACCESSWIRE · 21h ago
Novo Nordisk Seeing Younger Diabetes Patients
Novo Nordisk A/S CEO Lars Fruergaard Jorgensen said that the number of younger diabetes patients is on the rise, which he attributed to childhood obesity. He speaks to Francine Lacqua on "Bloomberg Surveillance: Early Edition." (Source: Bloomberg)
Bloomberg · 23h ago
New Trends in Obesity Management Market Size 2021
May 05, 2021 (MARKITWIRED via COMTEX) -- High costs involved in the research & development (R&D) of obesity drugs, coupled with limited financial...
Markitwired · 23h ago
Novo Nordisk's (NVO) Q1 Earnings and Sales Beat Estimates
Zacks.com · 23h ago
Aeterna Zentaris Reports First Quarter 2021 Financial Results and Provides Pipeline Program Updates
CHARLESTON, May 05, 2021 (GLOBE NEWSWIRE via COMTEX) -- - Q12021 marked by solid operational execution with expansion and diversification of pipeline,...
GlobeNewswire · 1d ago
Novo Nordisk boosts 2021 sales, profit growth outlook
Novo Nordisk (NVO) is upping both its sales and profit growth outlook for the year following Q1 earnings that beat on both sales and profit.For 2021, the Danish pharmaceutical company
Seekingalpha · 1d ago
Hormone Replacement Drugs Market Size 2021-2027 | Production Capacity Estimates, Industry On Going Trends, Development History, Regional Overview, Share Estimation, Revenue, and Business Prospect
May 05, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." The global “Hormone Replacement Drugs...
The Express Wire · 1d ago
LIVE MARKETS-UK: May 6th making history? Not really
reuters.com · 1d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NVO. Analyze the recent business situations of Novo Nordisk through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NVO stock price target is 79.80 with a high estimate of 80.45 and a low estimate of 79.16.
EPS
Institutional Holdings
Institutions: 910
Institutional Holdings: 146.25M
% Owned: 8.24%
Shares Outstanding: 1.78B
TypeInstitutionsShares
Increased
225
3.33M
New
93
817.52K
Decreased
218
5.98M
Sold Out
44
941.48K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.68%
Pharmaceuticals & Medical Research
+0.20%
Key Executives
Chairman/Independent Director
Helge Lund
President/Chief Executive Officer
Lars Fruergaard Joergensen
Vice Chairman/Director
Jeppe Christiansen
Chief Financial Officer/Executive Vice President/Primary Contact
Karsten Munk Knudsen
Chief Operating Officer/Executive Vice President
Maziar Doustdar
Executive Vice President/Chief Scientific Officer
Mads Krogsgaard Thomsen
Executive Vice President/Director of Human Resources
Monique Carter
Executive Vice President
Ludovic Helfgott
Executive Vice President
Doug Langa
Executive Vice President
Camilla Sylvest
Executive Vice President
Henrik Wulff
Director
Mette Boejer Jensen
Director
Kasim Kutay
Director
Anne Kverneland
Director
Thomas Rantzau
Director
Stig Stroebaek
Independent Director
Brian Daniels
Independent Director
Laurence Debroux
Independent Director
Andreas Fibig
Independent Director
Sylvie Gregoire
Independent Director
Liz Hewitt
Independent Director
Martin Mackay
Declaration Date
Dividend Per Share
Ex-Div Date
--
Dividend USD 0.6631491
03/26/2021
08/06/2020
Dividend USD 0.3679776
08/14/2020
02/06/2020
Dividend USD 0.5613016
03/27/2020
08/09/2019
Dividend USD 0.31809
08/16/2019
03/26/2019
Dividend USD 0.557215
03/22/2019
08/21/2018
Dividend USD 0.327
08/17/2018
--
Dividend USD 0.578
03/23/2018
08/10/2017
Dividend USD 0.336
08/17/2017
03/28/2017
Dividend USD 0.479
03/23/2017
08/16/2016
Dividend USD 0.331
08/11/2016
03/24/2016
Dividend USD 0.699
03/18/2016
03/25/2015
Dividend USD 0.533
03/19/2015
03/27/2014
Dividend USD 0.606
03/21/2014
03/26/2013
Dividend USD 0.453
03/21/2013
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

Webull offers kinds of Novo Nordisk A/S (ADR) stock information, including NYSE:NVO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NVO stock methods without spending real money on the virtual paper trading platform.